Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw strong trading volume on Wednesday . 9,073 shares traded hands during trading, an increase of 131% from the previous session’s volume of 3,931 shares.The stock last traded at $20.41 and had previously closed at $20.13.

Wall Street Analyst Weigh In

AAPG has been the subject of a number of recent analyst reports. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Stock Performance

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average price of $23.15 and a 200-day moving average price of $25.82.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million during the quarter. Equities research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently bought and sold shares of AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International in the third quarter worth about $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International during the third quarter valued at approximately $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Finally, XY Capital Ltd lifted its holdings in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.